Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
Mothe B. et al, (2019), EClinicalMedicine, 11, 65 - 80
Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine.
Rahim MN. et al, (2019), PLoS pathogens, 15
Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1
Borthwick NJ. et al, (2018), PLOS ONE, 13, e0197299 - e0197299
Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
Moyo N. et al, (2017), PLOS ONE, 12, e0181382 - e0181382
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
Hancock G. et al, (2017), Journal of the International AIDS Society, 20, 21171 - 21171
Mutua G. et al, (2016), Molecular Therapy - Methods & Clinical Development, 3, 16061 - 16061
Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial
Hayton E-J. et al, (2014), PLoS ONE, 9, e101591 - e101591